Evidence map›Paper›PMID 29453232›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2018

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Ayca Gucalp, Xi K Zhou, Elise D Cook, Judy E Garber, Katherine D Crew, Julie R Nangia, Priya Bhardwaj, Dilip D Giri, Olivier Elemento, Akanksha Verma and 15 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Obesity as a Risk Factor for Breast Cancer-The Role of miRNA.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 1 country.

Ayca GucalpDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. gucalpa@mskcc.org.
Xi K ZhouDepartment of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
Elise D CookDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Katherine D CrewDepartments of Medicine/Epidemiology, New York-Presbyterian/Columbia University Medical Center, New York, New York.
Julie R NangiaDepartment of Medicine, Baylor College of Medicine, Houston, Texas.
Priya BhardwajDepartment of Medicine, Weill Cornell Medical College, New York, New York.
Dilip D GiriDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Olivier ElementoDepartments of Physiology and Biophysics/Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Akanksha VermaDepartments of Physiology and Biophysics/Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Hanhan WangDepartment of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lana A VornikDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Carrie MaysDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Diane WeberDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Valerie SepedaDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Holly O'KaneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Margaret KrasneDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Samantha WilliamsDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Patrick G MorrisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Brandy M Heckman-StoddardDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
Barbara K DunnDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
Clifford A HudisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Powel H BrownDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew J DannenbergDepartment of Medicine, Weill Cornell Medical College, New York, New York.
The University of Texas MD Anderson Cancer Center · USCornell University · USMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USNational Cancer Institute · USAmerican Society of Clinical Oncology · USBaylor College of Medicine · USNewYork–Presbyterian Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
PHASE I and II CLINICAL TRIALS OF CHEMOPREVENTIVE AGENTS-261035159-261035159N01CN035159 · CN · UNIVERSITY OF TEXAS M D ANDER · PI LIPPMAN, SCOTT M. · 2004 to 2006
–
NCI NIH HHS N01 CN035159NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Obesity, a cause of subclinical inflammation, is a risk factor for the development of postmenopausal breast cancer and is associated with poorer cancer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment with DHA would reduce the expression of proinflammatory genes and aromatase, the rate-limiting enzyme for estrogen biosynthesis, in benign breast tissue of overweight/obese women. A randomized, placebo-controlled, double-blind phase II study of DHA given for 12 weeks to overweight/obese women with a history of stage I-III breast cancer, DCIS/LCIS, Paget's disease, or proliferative benign breast disease was carried out. In this placebo controlled trial, the primary objective was to determine whether DHA (1,000 mg by mouth twice daily) reduced breast tissue levels of TNFα. Secondary objectives included evaluation of the effect of DHA on breast tissue levels of COX-2, IL1β, aromatase, white adipose tissue inflammation, and gene expression by RNA-seq. Red blood cell fatty acid levels were measured to assess compliance. From July 2013 to November 2015, 64 participants were randomized and treated on trial (32 women per arm). Increased levels of omega-3 fatty acids in red blood cells were detected following treatment with DHA (

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDocosahexaenoic AcidsDouble-Blind MethodFemaleFibrocystic Breast DiseaseFollow-Up StudiesGene Expression ProfilingHumansMiddle AgedNeoplasm InvasivenessPrecancerous ConditionsPrognosisBiomarkers, TumorDocosahexaenoic Acids

Identifiers

PMID29453232
PMCPMC6290902
OpenAlexW2793240259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.